Correlation of clinical and in vitro erythropoietic responses to androgens in renal failure.
To assess in vitro erythropoietic cultures as a tool to discriminate between patients whose anemia improves with and those whose anemia fails to improve with androgens, bone marrows of 24 anemic patients receiving maintenance hemodialysis in hormone-depleted plasma clots were cultured. While erythroid colony proliferation in the presence and absence of androgens by cells of seven patients with good clinical outcomes who were initially studied was similar to that of normal donors, it was reduced (P less than 0.001) in cultures of cells from seven patients whose clinical responses were ultimately poor. Fewer than 25 colonies/6 X 10(4) cells at optimal erythropoietin concentrations, and less than a 25% enhancement in colony growth by androgens were observed in only those cultures derived from clinical nonresponder marrows. Using these criteria, nine of ten prospectively classified patients (five clinical responders and four nonresponders) were identified correctly.
D000328:Adult; D000368:Aged; D000738:Androsterone / Q000627:therapeutic use; D003114:Colony-Forming Units Assay; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000378:metabolism; D005260:Female; D005474:Fluoxymesterone / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009277:Nandrolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077603:Nandrolone Decanoate; D006435:Renal Dialysis; D013739:Testosterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D045165:Testosterone Congeners / Q000627:therapeutic use*
D045165:Testosterone Congeners; D004921:Erythropoietin; D013739:Testosterone; D009277:Nandrolone; C004648:testosterone enanthate; D005474:Fluoxymesterone; D000738:Androsterone; D000077603:Nandrolone Decanoate